NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias.
CD38
NK cells
multiple myeloma
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
21 03 2020
21 03 2020
Historique:
received:
13
02
2020
revised:
14
03
2020
accepted:
19
03
2020
entrez:
5
4
2020
pubmed:
5
4
2020
medline:
11
2
2021
Statut:
epublish
Résumé
Immunotherapy represents a promising new avenue for the treatment of multiple myeloma (MM) patients, particularly with the availability of Monoclonal Antibodies (mAbs) as anti-CD38 Daratumumab and Isatuximab and anti-SLAM-F7 Elotuzumab. Although a clear NK activation has been demonstrated for Elotuzumab, the effect of anti-CD38 mAbs on NK system is controversial. As a matter of fact, an initial reduction of NK cells number characterizes Daratumumab therapy, limiting the potential role of this subset on myeloma immunotherapy. In this paper we discuss the role of NK cells along with anti-CD38 therapy and their implication in plasma cell dyscrasias, showing that mechanisms triggered by anti-CD38 mAbs ultimately lead to the activation of the immune system against myeloma cell growth.
Identifiants
pubmed: 32245149
pii: cells9030768
doi: 10.3390/cells9030768
pmc: PMC7140687
pii:
doi:
Substances chimiques
ADP-ribosyl Cyclase 1
EC 3.2.2.6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Références
J Immunol. 2011 Feb 1;186(3):1840-8
pubmed: 21187443
Exp Hematol. 1993 Oct;21(11):1480-6
pubmed: 7691636
Blood. 2013 Feb 21;121(8):1345-56
pubmed: 23287865
J Immunol. 1997 Jul 1;159(1):184-92
pubmed: 9200454
Blood. 2002 Apr 1;99(7):2490-8
pubmed: 11895784
Cancer Immunol Immunother. 2015 Jan;64(1):61-73
pubmed: 25287778
N Engl J Med. 2019 May 30;380(22):2104-2115
pubmed: 31141632
Front Immunol. 2017 Nov 07;8:1444
pubmed: 29163516
Clin Cancer Res. 2015 Nov 15;21(22):5047-56
pubmed: 26567364
J Immunol. 1989 Nov 15;143(10):3183-91
pubmed: 2530273
Cancer Immunol Res. 2015 Jun;3(6):575-82
pubmed: 26041808
N Engl J Med. 2018 Feb 8;378(6):518-528
pubmed: 29231133
Front Immunol. 2018 Aug 13;9:1869
pubmed: 30150991
Blood. 1990 Oct 1;76(7):1375-9
pubmed: 2119828
Clin Cancer Res. 2017 Aug 1;23(15):4290-4300
pubmed: 28249894
Blood Cancer J. 2015 Jul 03;5:e321
pubmed: 26140429
Front Immunol. 2017 Sep 13;8:1124
pubmed: 28955340
J Immunol. 2015 Aug 1;195(3):965-72
pubmed: 26091716
Blood Cancer J. 2019 Mar 29;9(4):41
pubmed: 30926770
J Immunol. 1990 Aug 1;145(3):878-84
pubmed: 1695648
J Allergy Clin Immunol. 2013 Sep;132(3):536-544
pubmed: 23906377
J Clin Oncol. 2012 Jun 1;30(16):1953-9
pubmed: 22547589
Clin Cancer Res. 2018 Aug 15;24(16):4006-4017
pubmed: 29666301
Leukemia. 2003 Jan;17(1):171-4
pubmed: 12529675
Cancer Immunol Immunother. 1987;25(2):133-6
pubmed: 3664530
N Engl J Med. 2016 Aug 25;375(8):754-66
pubmed: 27557302
Cancer Immunol Immunother. 2018 Jun;67(6):861-872
pubmed: 29500635
J Innate Immun. 2015;7(6):563-71
pubmed: 25924651
Eur J Immunol. 1993 Oct;23(10):2407-11
pubmed: 8405040
Haematologica. 2014 Jun;99(6):e81-3
pubmed: 24658821
Clin Cancer Res. 2019 May 15;25(10):3176-3187
pubmed: 30692097
Blood. 2016 Mar 3;127(9):1151-62
pubmed: 26668134
Clin Cancer Res. 2015 Sep 15;21(18):4055-61
pubmed: 25999435
N Engl J Med. 2019 May 2;380(18):1726-1737
pubmed: 31042825
Immunol Res. 2006;35(3):263-78
pubmed: 17172651
N Engl J Med. 2015 Aug 13;373(7):621-31
pubmed: 26035255
Blood Adv. 2017 Oct 24;1(23):2105-2114
pubmed: 29296857
Nat Rev Immunol. 2011 Aug 26;11(10):645-57
pubmed: 21869816
J Immunol. 1990 Apr 1;144(7):2811-5
pubmed: 2319135
Cytometry. 1996 Jun 15;26(2):121-4
pubmed: 8817087
Leukemia. 2020 Jan;34(1):21-34
pubmed: 31780814
Blood. 2019 Jul 11;134(2):123-133
pubmed: 30862646
Front Immunol. 2018 Apr 13;9:704
pubmed: 29706958
Blood. 1999 Dec 1;94(11):3864-71
pubmed: 10572102
Blood. 1991 Mar 1;77(5):1071-9
pubmed: 1995092
Blood. 2016 Jul 21;128(3):384-94
pubmed: 27222480
FASEB J. 1998 May;12(7):581-92
pubmed: 9576485